Why the study?
Does disopyramide prevent recurrence of atrial fibrillation in patients undergoing electroconversion?
Population
52 patients undergoing electroconversion of atrial fibrillation
Comparison
Disopyramide vs Placebo
Design
RCT, double-blind
Follow-up
3 months
Authors
Loading...
Supports disopyramide after successful cardioversion; confirms RCT benefit versus placebo for sinus rhythm maintenance.
Does disopyramide prevent recurrence of atrial fibrillation in patients undergoing electroconversion?
Disopyramide significantly improves the maintenance of sinus rhythm at 3 months following electroconversion for atrial fibrillation compared to placebo.
Härtel et al. (1974) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: